source
- Roche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyoutRoche’s CEO has insisted to Fierce that the company’s view on its $1.5 billion Poseida buyout has “absolutely not” changed, even as the Swiss pharma scraps one of the CAR-T therapy’s from the acqui…Fierce Biotech · 5h ago↗ source
- Roche reports up to 30% shrinkage of chronic MS lesions with fenebrutinib, eyes FDA approvalRoche has filed for FDA approval of its BTK inhibitor fenebrutinib for both relapsing and primary progressive multiple sclerosis, after the agency accepted the submission. At the MSToronto2026 mee…